Overview

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

Status:
Terminated

Trial end date:
2018-10-23

Target enrollment:

Participant gender:

Summary

This is a Phase 3, dose-escalation study designed to evaluate the safety and efficacy of both elagolix alone and elagolix plus estradiol/norethindrone acetate (E2/NETA) over 24 months in the management of endometriosis with associated moderate to severe pain in premenopausal women.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Estradiol
Norethindrone
Norethindrone Acetate